Novo Nordisk to Pay Up to $2 Billion for Rights to Experimental Obesity and Diabetes Drug
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese pharmaceutical company The United Bio-Technology Co., as it looks to boost its pipeline of next-generation drugs.
Zacks Investment Research on MSN9h
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...
Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...
We recently published a list of 10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil. In this article, we are going ...
The issuer is solely responsible for the content of this announcement.
Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff ...
He added that the US market relies heavily on generic drugs rather than branded products, which Novo Nordisk does not sell. Competitor Eli Lilly (LLY) recently announced a $27 billion ...
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback